コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 pH 6.8, followed by 2 h at pH 7.4 (in vitro metabolic acidosis).
2 y acidosis) or through lactic acid infusion (metabolic acidosis).
3 bicarbonate therapy for patients with severe metabolic acidosis.
4 used in resuscitation can themselves produce metabolic acidosis.
5 e mixed acid-base disorders in patients with metabolic acidosis.
6 a further decrease of PMo2 by 68% and worse metabolic acidosis.
7 ponatremia, but in large volumes may lead to metabolic acidosis.
8 s led to new ways of managing hyperchloremic metabolic acidosis.
9 terone, with salt wasting, hyperkalemia, and metabolic acidosis.
10 al Lowe syndrome, none of these patients had metabolic acidosis.
11 ren deficient in enzyme activity have severe metabolic acidosis.
12 rbonate load, but there was no effect during metabolic acidosis.
13 d at rest, likely compensating for a chronic metabolic acidosis.
14 ertension, hyperkalemia, hyperchloremia, and metabolic acidosis.
15 w-grade, pathogenically significant systemic metabolic acidosis.
16 y impaired renal acid secretion resulting in metabolic acidosis.
17 potension, decreased urine output (UOP), and metabolic acidosis.
18 higher than that of controls, indicative of metabolic acidosis.
19 adaptation helps maintain homeostasis during metabolic acidosis.
20 e inner stripe of renal outer medulla during metabolic acidosis.
21 rupt acid-base balance, particularly causing metabolic acidosis.
22 Veverimer effectively and safely corrected metabolic acidosis.
23 l outcome (progression to hemodialysis), and metabolic acidosis.
24 evations in CBF induced via the ACZ-mediated metabolic acidosis.
25 r blood ketoacids; and 'A', a high anion gap metabolic acidosis.
26 unmeasured anions were the leading cause of metabolic acidosis.
27 sis in the whole cohort and in patients with metabolic acidosis.
28 arterial hypertension and hyperkalemia with metabolic acidosis.
29 evented IC subtype alterations and magnified metabolic acidosis.
30 I)--features hypertension, hyperkalemia, and metabolic acidosis.
31 ith weight loss, hypertonic dehydration, and metabolic acidosis.
32 luding hyperkalemia, hyperaldosteronism, and metabolic acidosis.
33 n in the papilla, and chronic hyperchloremic metabolic acidosis.
34 ely low in alphaICs, even when stimulated by metabolic acidosis.
35 ociated with hyperkalemia and hyperchloremic metabolic acidosis.
36 ogical tissue damage despite more pronounced metabolic acidosis.
37 ssium channel activation and respiratory and metabolic acidosis.
38 nd increased urinary acid elimination during metabolic acidosis.
39 c4a7) in rat brain is upregulated by chronic metabolic acidosis.
40 d plexus epithelia was unaffected by chronic metabolic acidosis.
41 ule reabsorption of bicarbonate resulting in metabolic acidosis.
42 tion of breathing elicited by hypercapnia or metabolic acidosis.
43 and hippocampal neurones was in response to metabolic acidosis (22 mm--> 14 mm HCO(3)(-)), which cau
44 l manifestations: cardiac (3.8 [2.88-4.91]), metabolic acidosis (3.7 [2.7-5.0]), renal failure (1.9 [
45 ackground ventilatory drive, increasing with metabolic acidosis (-6.7 mm Hg) and nonhypoxic periphera
49 have alkaline urine but do not exhibit overt metabolic acidosis, a renal phenotype similar to that of
50 on disease, metabolism abnormalities such as metabolic acidosis, abnormal fatty acid metabolism, hype
51 ular acidoses (dRTA), whose features include metabolic acidosis accompanied by disturbances of potass
52 udy randomized 1480 individuals with CKD and metabolic acidosis, across 320 sites to placebo or vever
54 at administration of AM/AMBP-1 would prevent metabolic acidosis after uncontrolled hemorrhage via dow
55 d with endothelial dysfunction (L-arginine), metabolic acidosis (alanine and lactate), and disease se
58 lood pressure, core temperature, and greater metabolic acidosis (analysis of variance, P < 0.0001).
59 out the study period; 1,609 met criteria for metabolic acidosis and 145 had normal acid-base values.
61 nal, bone and mineral metabolism, correcting metabolic acidosis and anemia, achieving excellent blood
64 ts in energy supply and demand can result in metabolic acidosis and diminished delivery and/or availa
65 eatures of MetS while also causing low-grade metabolic acidosis and elevating natriuretic peptides.
67 ensue from a mitochondrial dysfunction (e.g. metabolic acidosis and hyperthermia) and that MH-suscept
68 , veverimer safely and effectively corrected metabolic acidosis and improved subjective and objective
71 H(3)), an environmental pollutant leading to metabolic acidosis and liver and kidney toxicity; dimeth
72 tation with Hextend was associated with less metabolic acidosis and longer survival in this experimen
73 e prevents the development of hyperchloremic metabolic acidosis and may reduce the need for vasopress
75 rongly associated with mortality were severe metabolic acidosis and need for endotracheal intubation.
76 ciated with mortality, whereas patients with metabolic acidosis and noncardiac structural or chromoso
77 n reduced glycogen accumulation and improved metabolic acidosis and phosphaturia in the animals by no
78 ammonia excretion (UNH(4)) in patients with metabolic acidosis and postulated that UAG could be used
82 HF patients experienced faster correction of metabolic acidosis and tended to be more rapidly weaned
83 oplasty in childhood can lead to significant metabolic acidosis and that compensation with bone buffe
86 olloids are associated with a hyperchloremic metabolic acidosis, and a hypocoagulable state although
87 lloids) are associated with a hyperchloremic metabolic acidosis, and a hypocoagulable state, although
88 The patient developed cardiac arrhythmia, metabolic acidosis, and cardiac failure, which resulted
90 Persistent systolic hypotension, acidemia/metabolic acidosis, and elevated Pao2) after 24 hours of
92 dyspnea, peripheral edema), worsening eGFR, metabolic acidosis, and hyperkalemia inform the timing o
94 n, increased blood oxygen content, prevented metabolic acidosis, and improved 6-hour survival (42% in
95 d hyponatremia, hyperkalemia, hypercalcemia, metabolic acidosis, and increased serum lithium concentr
96 issive hypercapnia in the presence of shock, metabolic acidosis, and multi-organ system dysfunction m
97 %) patients died due to acute kidney injury, metabolic acidosis, and multiple organ dysfunction syndr
98 membrane oxygenation, development of severe metabolic acidosis, and number of early extubations in t
99 increased expression in response to chronic metabolic acidosis, and originally was cloned as a tumor
100 ed by processes other than the post-exercise metabolic acidosis, and that changes in peripheral chemo
101 scle protein breakdown include inflammation, metabolic acidosis, angiotensin II, and neural and hormo
102 id excretion and bicarbonate reabsorption in metabolic acidosis are closely similar to those operativ
103 Although the protein catabolic effects of metabolic acidosis are well established, it is unclear w
104 -center prospective studies identify chronic metabolic acidosis as an independent and modifiable risk
105 provement in hemodynamics, urine output, and metabolic acidosis, as well as a perceived increase in s
108 erely injured trauma patients, the degree of metabolic acidosis at the time of admission identified t
110 n two study groups: children presenting with metabolic acidosis (base deficit >8) and children withou
118 d acidotic rats is mediated by NHE3 and that metabolic acidosis causes increased expression of renal
119 lp to preserve muscle oxygenation and reduce metabolic acidosis compared with CLE at the same average
121 A subsequent renally mediated compensatory metabolic acidosis corrects pH toward baseline values, w
123 l metabolism, in addition to roles played by metabolic acidosis, cytokines, and degradation of parath
124 cluding urinary tract infections, hematuria, metabolic acidosis, dehydration, and reflux pancreatitis
125 Evaluation II score, mechanical ventilation, metabolic acidosis, delirium on the prior day, and coma
126 acidosis with blood pH </= 7.15, persistent metabolic acidosis despite adequate supportive measures
127 dehydration, hypotension, hyperkalaemia and metabolic acidosis, despite elevated aldosterone levels.
128 nd shock refractory to inotropic agents, and metabolic acidosis developed in the patient within 2 hou
129 er of pathophysiologic conditions, including metabolic acidosis, diabetes, sepsis, and high angiotens
131 ated by liver failure, renal failure, severe metabolic acidosis, disseminated intravascular coagulopa
132 ences, is characterized by hyperglycemia and metabolic acidosis due to the accumulation of ketone bod
133 y as capable as control livers in correcting metabolic acidosis during the first 24 hr posttransplant
135 weaning grew to adulthood; however, they had metabolic acidosis, elevated blood concentrations of Na(
136 nate synthesis from glutamine during chronic metabolic acidosis facilitate the excretion of acids and
137 gh energy phosphate stores and correction of metabolic acidosis following brief periods of global isc
139 acidosis (pRTA), a disease characterized by metabolic acidosis, growth retardation, ocular abnormali
141 y massive urinary excretion of 5-oxoproline, metabolic acidosis, haemolytic anaemia and central nervo
142 ll alkali supplementation trials, correcting metabolic acidosis has a strikingly broad array of poten
143 known to decrease bone mineral density, and metabolic acidosis has been shown to increase glucocorti
145 me featuring hypertension, hyperkalaemia and metabolic acidosis, has revealed previously unrecognized
147 and proinflammatory mediators and correcting metabolic acidosis, high-volume hemofiltration (HVHF) mi
148 renal insufficiency, high plasma potassium, metabolic acidosis, hydronephrosis of varying severity,
149 erventions specifically targeting hypoxemia, metabolic acidosis, hyperglycemia, and cardiovascular in
150 disease (CKD), such as anemia, hypertension, metabolic acidosis, hyperkalemia, or persistent secondar
151 complications of CKD, such as hyperkalemia, metabolic acidosis, hyperphosphatemia, vitamin D deficie
153 ning, Atp6v0a4(-/-) mice demonstrated severe metabolic acidosis, hypokalemia, and early nephrocalcino
154 These results suggest that during acute metabolic acidosis, IMCD 11 beta-HSD2 is inhibited and m
156 definitive trial testing whether correcting metabolic acidosis improves clinical outcomes has not be
158 E-subunit; however, the greater severity of metabolic acidosis in Atp6v1b1(-/-) mice after oral acid
160 abrogation of weight loss, dehydration, and metabolic acidosis in inoculated pigs, and LT complement
161 y and safety of veverimer as a treatment for metabolic acidosis in patients with chronic kidney disea
162 symptoms, secondary hyperparathyroidism, and metabolic acidosis in patients with chronic renal failur
163 with higher risks of long-term dialysis and metabolic acidosis in patients with POAG and pre-dialysi
164 a demonstrating the benefits of azotemia and metabolic acidosis in survival of patients with metastat
165 tion (H+ secretion) in OMCD is stimulated by metabolic acidosis in vivo and in vitro by an increase i
166 that the osteopenia observed in response to metabolic acidosis in vivo is not due to an increase in
167 chemical and cell-mediated bone responses to metabolic acidosis, in addition to an acidosis-induced i
168 n after hemorrhagic shock is associated with metabolic acidosis, in which the up-regulated endothelin
169 to assess other deleterious consequences of metabolic acidosis including progression of chronic kidn
173 etion by the kidney and resulted in a nongap metabolic acidosis, indicating that GPR4 is required to
176 of osteoclast OGR1 decreased both basal and metabolic acidosis-induced osteoclast activity indicatin
177 NH4Cl gavage in the neonatal rat produces a metabolic acidosis-induced retinopathy which serves as a
179 strated that saline may cause hyperchloremic metabolic acidosis, inflammation, hypotension, acute kid
180 li that initiate muscle protein loss include metabolic acidosis, insulin and IGF1 resistance, changes
183 In summary, the hypocitraturia of chronic metabolic acidosis is associated with an increase in ATP
187 entifying these individuals with subclinical metabolic acidosis is challenging, but recent results su
191 sed brush border Na+-H+ exchange observed in metabolic acidosis is due to increased expression of NHE
193 f the rat renal glutaminase (GA) mRNA during metabolic acidosis is mediated by a pH-response element
198 ock, as measured by systemic hypotension and metabolic acidosis, is significantly associated with a h
200 tomy and urinary diversion may cause chronic metabolic acidosis, leading to long-term bone loss in pa
202 intractable myocardial failure preceded by a metabolic acidosis, lipaemic plasma, fatty infiltration
208 ular acidification during the early phase of metabolic acidosis (MAc), not just in neurons but, surpr
210 paired acid excretion in CKD, with potential metabolic acidosis, may contribute to the progression of
211 opics and the prevalence and risk factors of metabolic acidosis, mechanisms of acid-mediated organ in
212 cate that AM/AMBP-1 administration prevented metabolic acidosis, mitigated organ injury, down-regulat
213 mal babies, and those with mixed respiratory/metabolic acidosis (more profound and prolonged hypoxia)
214 the shock-related lactic acidosis but caused metabolic acidosis, most likely resulting from reduced c
216 y urine, variable hyperchloremic hypokalemic metabolic acidosis, nephrocalcinosis, and nephrolithiasi
217 e of a normal salt intake led to a degree of metabolic acidosis not significantly different from that
219 Atp6v1b1vxt/vtx mice do not recapitulate the metabolic acidosis of dRTA patients, they provide a new
220 In patients with CKD, untreated chronic metabolic acidosis often leads to an accelerated reducti
221 resent study addressed the effect of chronic metabolic acidosis on a cytosolic enzyme of citrate meta
222 omized trials testing the effect of treating metabolic acidosis on slowing CKD progression have not b
223 abolism; it was confounded by the effects of metabolic acidosis on the CO(2)-hemoglobin dissociation
226 ECLS, patients who develop renal failure or metabolic acidosis or undergo venoarterial ECLS should b
229 g-term dialysis, and cumulative incidence of metabolic acidosis over time between CAI users and CAI n
230 tions include volume overload, hyperkalemia, metabolic acidosis, overt uremia, and even progressive a
232 Mice infected with P. berghei exhibit (i) metabolic acidosis (pH < 7.3) associated with elevated p
233 icipated events were categorized as isolated metabolic acidosis (pH <7.20), hypercapnia (P(CO2), >70
234 petitive substrate methylaminoisobutyrate or metabolic acidosis (pH 7.1) depleted intracellular L-Gln
236 igh urea serum levels [>= 150 mg/dL], severe metabolic acidosis [pH <= 7.15], oliguria [urinary outpu
237 of a trauma patient with severe unexplained metabolic acidosis, possibly attributable to the vasocon
238 creased urinary calcium excretion induced by metabolic acidosis predominantly results from increased
241 3 days included hyperglycemia with resultant metabolic acidosis, pulmonary dysfunction, nausea, vomit
242 owing criteria was met: severe hyperkalemia, metabolic acidosis, pulmonary edema, blood urea nitrogen
244 rdiac symptoms, rhabdomyolosis, hypotension, metabolic acidosis, renal failure, and age each affected
246 per 1 mg/dl increase in total bilirubin) and metabolic acidosis (RR, 0.95; 95% CI, 0.90 to 0.99 per 1
247 tration rate 20-40 mL/min per 1.73 m(2)) and metabolic acidosis (serum bicarbonate 12-20 mmol/L), who
248 tion rate of 20-40 mL/min per 1.73 m(2)) and metabolic acidosis (serum bicarbonate concentration of 1
249 CKD (eGFR of 20-40 ml/min per 1.73 m 2 ) and metabolic acidosis (serum bicarbonate of 12-20 mEq/L) fr
251 effects on osteoclast OGR1 are critical for metabolic acidosis stimulated bone resorption, we genera
252 Water supplementation with NH(4)Cl to induce metabolic acidosis stimulated Piezo1 activity in ICs but
257 xcrete endogenous acid, resulting in chronic metabolic acidosis that increases the risk of disease pr
258 kidney dysfunction include hyperkalemia and metabolic acidosis that occur at higher eGFR thresholds
259 ation of trauma patients, may exacerbate the metabolic acidosis that occurs with injury, and this aci
260 current oral sodium bicarbonate therapy for metabolic acidosis that only neutralises accumulated aci
262 ervation of visual acuity, the resolution of metabolic acidosis, the inhibition of formic acid produc
264 urones indicates that, except in response to metabolic acidosis, the neurones from the chemosensitive
266 eating Western diets have chronic, low-grade metabolic acidosis, the severity of which is determined
267 During long-term studies to model chronic metabolic acidosis, there is also inhibition of osteobla
268 During short-term studies to model acute metabolic acidosis, there is initial physiochemical bone
272 arterial hypertension with hyperkalemia and metabolic acidosis, unmasked a complex multiprotein syst
274 In patients with chronic kidney disease and metabolic acidosis, veverimer safely and effectively cor
275 g acid-base balance (control); (2) following metabolic acidosis via 2 days of oral acetazolamide at 2
277 ed stepwise alterations in PaCO(2) following metabolic acidosis (via 2 days of oral acetazolamide; AC
278 In treated animals, urine output was higher, metabolic acidosis was attenuated, and renal tubular arc
280 lated from rats with 5 days of NH4Cl-induced metabolic acidosis was increased 1.5-fold compared with
284 antibody-treated animals, UOP was decreased, metabolic acidosis was worsened, and median survival tim
285 on, as reflected by a hyperosmolar anion gap metabolic acidosis, was observed in critically ill adult
287 base deficit (as a reflection of severity of metabolic acidosis) were recorded immediately before the
289 locking muscle wasting include correction of metabolic acidosis, which can suppress muscle protein lo
290 onia metabolism in the kidney in response to metabolic acidosis, which provides mechanistic insights
292 osis in humans, a condition characterized by metabolic acidosis with an inappropriately alkaline urin
293 thanol: coma, seizures, new vision deficits, metabolic acidosis with blood pH </= 7.15, persistent me
294 denced by a high anion gap (> or =15 mmol/L) metabolic acidosis with elevated osmol gap (> or =10 mOs
295 s of autosomal recessive dRTA include severe metabolic acidosis with inappropriately alkaline urine,
296 spiratory alkalosis developed, followed by a metabolic acidosis with increased levels of blood lactat
298 oad, whereas Rhcg(-/-) mice developed severe metabolic acidosis with reduced ammonuria and high morta
299 actic, unmeasured anions, and hyperchloremic metabolic acidosis with that of patients without acid-ba
300 associated with neurological recovery while metabolic acidosis x TTI 5.7 min (OR: 3.63, 95% CI 1.36-